3% of measles cases are among fully vaccinated individuals, CDC says
Measles infections in the U.S. have reached nearly 1,200 in 2025 as cases continue to crop up in 35 states. At least 3% of those cases have been in people who received two doses of the MMR measles vaccine, meaning they were fully vaccinated, according to the Centers for Disease Control and Prevention. In 2% of confirmed measles cases, the person had received one MMR dose.
The last measles outbreak of a similar scale occurred in 2019, when a total of 1,274 cases were confirmed across the country. However, 2025 is shaping up to be the largest outbreak in 25 years. There have been three confirmed measles deaths, two children and one adult, thus far in 2025.
Measles vaccines are 97% effective at preventing measles after two doses and 93% after one dose, according to the CDC. The disease was previously eradicated in the U.S. in 2000, meaning there was no spread and new cases were only those contracted from abroad. Vaccine rates have declined by an average of 2.67% in most U.S. counties over the past five years, according to data published by John Hopkins University, resulting in a growing number of states moving further away from the 95% herd immunity threshold.
The effectiveness of the measles vaccine depends on the timing of vaccination and the nature of the exposure. "If the vaccine is administered within three days of exposure to measles in "limited" contact settings (e.g., schools, childcare, and medical offices)," it may "provide some protection against infection or modify the clinical course of disease," the agency's recommendations say. However, postexposure vaccination "does not appear to be effective in settings with intense, prolonged, close contact, such as households and smaller childcare facilities."
Health and Human Services Secretary Robert F. Kennedy Jr. has been widely labeled as a vaccine skeptic. But on April 6, he wrote in a lengthy post on X that "the most effective way to prevent the spread of measles is the MMR vaccine."
More: RFK Jr. MMR vaccine support spurs backlash: 'So much for MAHA'
USA TODAY has reached out to the CDC for comment.
This article originally appeared on USA TODAY: Measles cases: 3% are among fully vaccinated individuals, per CDC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
LSU picks search committee members to find its next president
LSU's Memorial Tower on Monday, March 20, 2023, on Tower Drive in Baton Rouge. (Matthew Perschall for Louisiana Illuminator) A search committee has been assembled to find LSU's next president. LSU is searching for a replacement for William Tate, who led both its Baton Rouge flagship campus and the LSU System that also includes medical schools in New Orleans and Shreveport, a New Orleans dental school and satellite institutions in Shreveport, Alexandria and Eunice. Tate departed Baton Rouge to become the leader of Rutgers University in New Jersey. Earlier this year, two board members confirmed to the Illuminator there is ongoing discussion over whether LSU will hire a system president and a separate chancellor for the its main campus. The school's news release announcing search committee members did not indicate whether there would be a separate search for a chancellor. LSU combined the two roles in 2012. Matt Lee, the dean of LSU's College of Agriculture, is serving as interim president. LSU Board of Supervisors chairman Scott Ballard announced the following list of individuals have been appointed to the 2025 LSU Presidential Search Committee, including himself as a member: Lee Mallett, LSU Board of Supervisors vice chairman Valencia Sarpy Jones, LSU Board of Supervisors past chair Rémy Voisin Starns, LSU Board of Supervisors past chair James Williams, LSU Board of Supervisors past chair John Carmouche, LSU Board of Supervisors Blaise Zuschlag, LSU Board of Supervisors Ben Bordelon, Bollinger Shipyards president and CEO Clarence Cazalot, LSU Foundation Board of Directors Paul Coreil, LSU Alexandria chancellor Greg Feirn, LCMC Health CEO E.J. Kuiper, Franciscan Missionaries of Our Lady Health System president & CEO Pete November, Ochsner Health CEO Roger Odgen, LSU Foundation Board of Directors Emily Otken, LSU Health Sciences Center Shreveport student, former LSU Board of Supervisors student member Kenneth Schafer, LSU Boyd professor and Ball Family distinguished professor Ryan Theriot, Former LSU baseball player Daniel Tirone, LSU A&M Faculty Senate president, associate professor Bill Windham, Shreveport-Bossier businessman Ballard told the Illuminator recently the board he predicts would work over the next six months or so to conduct a nationwide search for Tate's replacement. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Yahoo
an hour ago
- Yahoo
Meyer signs executive order shielding patients and providers of gender-affirming care
A newly signed executive order makes information on gender-affirming care more secure. Executive Order 11 was signed on June 10 in Rehoboth Beach. The order protects patients and providers from being forced to hand over information about gender-affirming care given in Delaware in most civil and criminal investigations and professional disciplinary actions. Medical records, data and billing information are included in the executive order. The executive order defines gender-affirming care as "any medically necessary healthcare or treatment consistent with current clinical standards of care prescribed by a licensed healthcare provider for the treatment of a condition related to the individual's gender identity and that is legal under Delaware law." The order forbids state agencies from supplying information on patients and providers of gender-affirming care in a civil or criminal investigation that is solely initiated on people providing, receiving, inquiring about, or responding to an inquiry regarding gender-affirming care or people traveling to Delaware to receive it. It also protects from out-of-state subpoenas. There are exceptions, like if there is a final and non-appealable court order or if required by federal or state law. The order also does not allow any medical boards in the state to bar or discipline providers of gender-affirming care on that lone basis. 'You can never erase us': Delaware bill to ban transgender care stalls, climate remains The order is designed to secure providers and patients from "hostile laws" in states that restrict gender-affirming care, a release from the governor's office said. 'Across the country, people are being punished for seeking or providing gender-affirming care,' said Gov. Matt Meyer in a statement on June 20. 'In Delaware, we cherish privacy, dignity and the right to make personal medical decisions. Everyone deserves the freedom to access healthcare rooted in science and compassion.' These restrictions are not unheard of. Delaware neighbors New Jersey and Maryland have very similar protections on the books. Shane Brennan covers Wilmington and other Delaware issues. Reach out with ideas, tips or feedback at slbrennan@ This article originally appeared on Delaware News Journal: DE executive order shields gender-affirming care patients, providers
Yahoo
an hour ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
